Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

Disclaimer

The content provided on this website by SIOPEN (International Society of Paediatric Oncology Europe – Neuroblastoma) is intended solely for informational and educational purposes, particularly to support collaboration and research among healthcare professionals involved in the care of children with neuroblastoma.

This website is not intended for clinical use or for providing direct medical advice. It should not be used to guide individual patient care decisions.

We understand that parents and caregivers may come across this site during what is often a very difficult and overwhelming time. Please know that while SIOPEN is a network of healthcare professionals and researchers deeply committed to improving outcomes for children with neuroblastoma, we are not able to offer individual medical advice or respond directly to clinical questions from families via this platform.

If you are seeking guidance, we strongly encourage you to speak with your child’s medical team, who are best placed to support you. Where necessary, they may reach out to a national SIOPEN representative or external expert for further input.

SIOPEN is carefully exploring ways to help facilitate professional-to-professional connections, always with patient care, safety and ethical standards as our highest priorities.